|
|
|
| Short-term effect of Xuezhikang Capsules combined with Valsartan on sclerotic stage of hypertensive retinopathy |
| LI Yanping1 LIU Sheng2 |
1.Department of Ophthalmology, the Fourth People′s Hospital of Linfen, Shanxi Province, Linfen 041000, China;
2.Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China |
|
|
|
Abstract Objective To observe the short-term effect of Xuzhikang Capsules combined with Valsartan in the treatment of patients with hypertensive retinopathy. Methods The subjects in 60 cases with 106 eyes were from the Fourth People′s Hospital of Linfen from January 2012 to July 2015, and they were divided into control group and treatment group by random number table, with 30 cases in each group. The two groups were underwent routine treatment to ensure that the test was carried out with the patient′s blood pressure up to standard. The observation group was additionally treated with Xuezhikang Capsules. The clinical efficacy was evaluated at 8 weeks after treatment. Results After treatment, the systolic blood pressure in the two groups and diastolic blood pressure in the control group were decreased (P < 0.05). The cure rate and total efficiency of treatment group were higher than those of control group (P < 0.05). The mend matters of retinal arterial spasm and vascular wall reflex in treatment group were better than those in the control group (P < 0.05). Conclusion The short-term effect of Xuzhikang Capsules combined with Valsartan in treating vision, fundus angiography and hypertension on sclerotic stage of hypertensive retinopathy is better.
|
|
|
|
|
|
[1] 陈红.2型糖尿病患者发生糖尿病视网膜病变的影响因素分析[J].江苏医药，2017，43（8）：592-594.
[2] 金琴辉.联合手术治疗老年性白内障合并特发性黄斑前膜的临床疗效[J].中国全科医学，2015，21（12）：129-130.
[3] 侯忠敏，荣运久.眼科基础与临床问答[M].北京：人民军医出版社，1998.
[4] 王小玲，胡咏梅.糖尿病患者视网膜病变患病率及影响因素分析[J].中国现代医生，2015，12（2）：14-16，23.
[5] 段宏辉.糖尿病患者视网膜病变高危因素分析[J].实用预防医学，2014（6）：499-501.
[6] 张廷杰，吴时达. 1999年世界卫生组织及国际高血压协会(WHO/ISH)高血压处理指南(第四次修订版)[J].心血管病学进展，1999（3）：177-144.
[7] Takahashi K，Roger A，Brooks，et al. Production of endothelin I by curtured bovine retinal endoth elial of cells and presence of end othelin receptors on associated pericytes [J]. Diabetes，1989，38（9）：120-123.
[8] 何洁，郝改梅，武志黔.活血解毒方对糖尿病大鼠视网膜病变的影响研究[J].中国全科医学，2015，18（5）：507-512.
[9] Nagai N，Noda K，Urano T，et al. Selective suppression of pathologic，but not physiologic，retinal neovascularization by blocking the angiotensin Ⅱ type 1 receptor [J]. Invest Ophthalmol Vis Sci，2005，46（3）：1078-1084.
[10] Wilkinson-Berka JL，Fletcher EL. Angiotensin and bradykinin：targets for the treatment of vascular and neuro-glial pathology in diabetic retinopathy [J]. Curr Pharm Des，2004，10（27）：3313-3330.
[11] Thomas R. Type 2 diabetes mellitus in children and adolescents [J]. World J Diabetes，2013，4（6）：2339-2346.
[12] Phipps JA，Wilkinson-Berka JL，Fletcher EL. Retinaldysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol [J]. Invest Ophthalmol Vis Sci，2007，48（2）：927-934.
[13] Guan G，Hui H，Yang Y，et al. Neferine prevented hyperglycemia induced endothelial cell apoptosis through suppressing ROS /Akt/NF-κB signal [J]. Endocrine，2014，47（3）：2198-2121.
[14] 刘欣跃，隋向前，李春凤.原发性高血压患者血清转化生长因子、胰岛素样生长因子含量变化及相关因素研究[J].国际检验医学杂志，2006，27（3）：215-216.
[15] Zhu Y，Zhang XL，Zhu BF，et al. Effect of antioxidant N-acetylcysteine on diabetic retinopathy and expression of VEGF and ICAM-1 from retinal blood vessels of diabetic rats [J]. Mol Biol Rep，2012，12（4）：1789-1793.
[16] 王倩，宗莲，刘斐霞.上海市残疾人眼科检查结果分析[J].中国全科医学，2016，19（34）：4234-4239.
[17] 李雨露，李一梅，谢波，等.缬沙坦和贝那普利治疗原发性高血压左室肥厚效果比较的系统评价[J].中国医药导报，2017，14（9）：136-141.
[18] 余腊梅，吕菊兰.三七粉治疗缺血性视网膜病变的临床观察[J].湖北中医杂志，2016，38（8）：44-45.
[19] 卢益中，徐建欧，朱春海，等.血脂康胶囊对颈动脉粥样硬化斑块的影响[J].海峡药学，2011，23（11）：13-15.
[20] 杨宇，袁敏而，于珊珊.家族性渗出性玻璃体视网膜病变相关的孔源性视网膜脱离患者对侧眼临床特征[J].中山大学学报：医学科学版，2015，36（2）：313-316. |
|
|
|
